Study Comparing Glofitamab and Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Untreated Large B-Cell Lymphoma Patients

Inclusion Criteria

• Have not received any previous treatment for large B-cell lymphoma (LBCL) and have CD20-positive LBCL.
• Able to provide a sample of tumor tissue.
• Have an International Prognostic Index (IPI) score between 2 and 5.
• Have a performance status score of 0, 1, or 2, indicating full activity or some restriction in strenuous activities.
• Have at least one tumor that can be measured by a scan and is larger than 1.5 cm.
• Have a heart function of 50% or higher as measured by specific heart tests.
• Have adequate blood cell counts and organ function.
• Test negative for HIV, with some exceptions.
• Test negative for COVID-19.

Exclusion Criteria

• Cannot have allergies or reactions to any of the study drugs or their components.
• Cannot have had a solid organ transplant.
• Cannot be taking certain immune-suppressing medications within four weeks before starting the study.
• Cannot have severe nerve damage or certain nerve diseases.
• Cannot have a history of slow-growing lymphomas or certain other types of lymphoma.
• Cannot have lymphoma that has spread to the brain or spinal cord.
• Cannot have received certain cancer treatments within the past three months.
• Cannot have had radiation therapy to the chest area.
• Cannot have had previous treatment for LBCL, except for steroids.
• Cannot be taking high doses of steroids for reasons other than lymphoma.
• Cannot have other cancers that might interfere with the study.
• Cannot have significant heart disease.
• Cannot have had major surgery recently.
• Cannot have certain brain or nervous system diseases.
• Cannot have certain viral infections or a history of certain immune system disorders.
• Cannot have active autoimmune diseases that are not well controlled.
• Cannot have significant liver disease.
• Cannot have received a live vaccine recently or plan to during the study.
• Cannot have an active infection or tuberculosis.
• Cannot have chronic hepatitis B, hepatitis C, or HTLV-1 infections.
• Cannot have a history of a specific brain infection.